lisofylline

Lisofylline is a synthetic small molecule and a metabolite of pentoxifylline with anti-inflammatory and immunomodulatory properties. It was under development as an investigational drug primarily for the prevention and treatment of type 1 diabetes mellitus. Lisofylline acts by blocking interleukin‑12 (IL‑12) signaling and STAT4 activation, key pathways involved in inflammation and autoimmune damage to insulin-producing pancreatic beta cells. Preclinical studies demonstrated that lisofylline can prevent the onset of autoimmune diabetes in animal models by suppressing proinflammatory cytokines such as IFN-gamma, TNF-alpha, IL‑1 beta, and IL‑6. Additionally, it improves mitochondrial function in cells and has shown potential to reduce complications associated with diabetes by protecting kidney cells from glucose-induced changes. Lisofylline has also been investigated for its ability to improve the viability of isolated or transplanted pancreatic islets[1][2][3][6][7].

Brand names

ProTec

Other names

lisofylline(R)-lisofylline1-(5-hydroxyhexyl)-3,7-dimethylxanthine3,7-dimethyl-1-(5-hydroxyhexyl)xanthineLisophylline(R)-lisophyllineProTec